These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 15087378)
1. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cybulski C; Huzarski T; Górski B; Masojć B; Mierzejewski M; Debniak T; Gliniewicz B; Matyjasik J; Złowocka E; Kurzawski G; Sikorski A; Posmyk M; Szwiec M; Czajka R; Narod SA; Lubiński J Cancer Res; 2004 Apr; 64(8):2677-9. PubMed ID: 15087378 [TBL] [Abstract][Full Text] [Related]
2. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; Gliniewicz B; Sikorski A; Stawicka M; Godlewski D; Kwias Z; Antczak A; Krajka K; Lauer W; Sosnowski M; Sikorska-Radek P; Bar K; Klijer R; Zdrojowy R; Małkiewicz B; Borkowski A; Borkowski T; Szwiec M; Narod SA; Lubiński J J Med Genet; 2006 Nov; 43(11):863-6. PubMed ID: 17085682 [TBL] [Abstract][Full Text] [Related]
3. CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population. Bayram S; Topaktaş M; Akkız H; Bekar A; Akgöllü E Cancer Epidemiol; 2012 Oct; 36(5):453-7. PubMed ID: 22521562 [TBL] [Abstract][Full Text] [Related]
4. Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? Cybulski C; Wokołorczyk D; Kładny J; Kurzawski G; Suchy J; Grabowska E; Gronwald J; Huzarski T; Byrski T; Górski B; D Ecedil Bniak T; Narod SA; Lubiński J Eur J Hum Genet; 2007 Feb; 15(2):237-41. PubMed ID: 17106448 [TBL] [Abstract][Full Text] [Related]
5. A personalised approach to prostate cancer screening based on genotyping of risk founder alleles. Cybulski C; Wokołorczyk D; Kluźniak W; Kashyap A; Gołąb A; Słojewski M; Sikorski A; Puszyński M; Soczawa M; Borkowski T; Borkowski A; Antczak A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Domagała P; Piotrowski K; Menkiszak J; Krzystolik K; Gronwald J; Jakubowska A; Górski B; Dębniak T; Masojć B; Huzarski T; Muir KR; Lophatananon A; Lubiński J; Narod SA; Br J Cancer; 2013 Jun; 108(12):2601-9. PubMed ID: 23722471 [TBL] [Abstract][Full Text] [Related]
6. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; van de Wetering T; Narod SA; Lubiński J Breast Cancer Res Treat; 2007 Mar; 102(1):119-22. PubMed ID: 16897426 [TBL] [Abstract][Full Text] [Related]
8. CHEK2 mutations and the risk of papillary thyroid cancer. Siołek M; Cybulski C; Gąsior-Perczak D; Kowalik A; Kozak-Klonowska B; Kowalska A; Chłopek M; Kluźniak W; Wokołorczyk D; Pałyga I; Walczyk A; Lizis-Kolus K; Sun P; Lubiński J; Narod SA; Góźdż S Int J Cancer; 2015 Aug; 137(3):548-52. PubMed ID: 25583358 [TBL] [Abstract][Full Text] [Related]
9. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations. Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998 [TBL] [Abstract][Full Text] [Related]
10. CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden. Wagenius M; Borg A; Johansson L; Giwercman A; Bratt O Scand J Urol Nephrol; 2006; 40(1):23-5. PubMed ID: 16452051 [TBL] [Abstract][Full Text] [Related]
11. CHEK2 variant I157T may be associated with increased breast cancer risk. Kilpivaara O; Vahteristo P; Falck J; Syrjäkoski K; Eerola H; Easton D; Bartkova J; Lukas J; Heikkilä P; Aittomäki K; Holli K; Blomqvist C; Kallioniemi OP; Bartek J; Nevanlinna H Int J Cancer; 2004 Sep; 111(4):543-7. PubMed ID: 15239132 [TBL] [Abstract][Full Text] [Related]
12. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Bell DW; Kim SH; Godwin AK; Schiripo TA; Harris PL; Haserlat SM; Wahrer DC; Haiman CA; Daly MB; Niendorf KB; Smith MR; Sgroi DC; Garber JE; Olopade OI; Le Marchand L; Henderson BE; Altshuler D; Haber DA; Freedman ML Int J Cancer; 2007 Dec; 121(12):2661-7. PubMed ID: 17721994 [TBL] [Abstract][Full Text] [Related]
15. A risk of breast cancer in women - carriers of constitutional CHEK2 gene mutations, originating from the North - Central Poland. Bąk A; Janiszewska H; Junkiert-Czarnecka A; Heise M; Pilarska-Deltow M; Laskowski R; Pasińska M; Haus O Hered Cancer Clin Pract; 2014 Apr; 12(1):10. PubMed ID: 24713400 [TBL] [Abstract][Full Text] [Related]
16. Association of two mutations in the CHEK2 gene with breast cancer. Bogdanova N; Enssen-Dubrowinskaja N; Feshchenko S; Lazjuk GI; Rogov YI; Dammann O; Bremer M; Karstens JH; Sohn C; Dörk T Int J Cancer; 2005 Aug; 116(2):263-6. PubMed ID: 15810020 [TBL] [Abstract][Full Text] [Related]
17. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168 [TBL] [Abstract][Full Text] [Related]